| Methods |
Design:
Double‐blind
randomized
placebo controlled
crossover study
(1 week X 2) |
| Participants |
Country: USA
Number: 23 patients
Sex: 12 males, 11 females
Age: 53‐89 years (mean of 66 years)
Diagnosis criteria: NINCDS‐ADRDA
Other possible causes of dementia were ruled out by laboratory tests
CT scans and EEGs were normal
Severity of AD: Mild to moderate cognitive impairment.
Patients scores on the Mattis Dementia Rating Scale (maximum possible score, 144): 81‐140 (mean of 115). |
| Interventions |
1. placebo
2. oral physostigmine optimal dose
Doses: Not specified |
| Outcomes |
Delayed Recognition Span Test (DRST)
BSRT
ADAS
BNT
Digit span
Figure copy |
| Notes |
Details on administration scheme, including doses, are not available in this paper.
One patient was excluded from the analysis (missing data due to inability to carry out some of the tests) |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
